# US 2019/0375776 A1 · Idiopathic pulmonary fibrosis-detection, monitoring, prediction methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375776 A1
- Document ID: US20190375776A1
- Status: Published application
- Kind: A1
- Application number: 16/531,122
- Filed: 2019-08-05
- Published: 2019-12-12
- Earliest claimed: 2012-10-31
- Assignees: Galecto Biotech AB
- Applicants: Galecto Biotech AB
- Inventors: Neil Henderson; Tariq Sethi; Alison Mackinnon; Hakon Leffler; Ulf Nilsson
- Web page: https://patentgrep.com/patent/US20190375776A1

## CPC

- C07H 19/056: Triazole or tetrazole radicals
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- C07H 3/04: Disaccharides
- C07H 5/10: to sulfur
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61M 15/0085: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 2202/064: Powder
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- G01N 2333/4724: Lectins
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

## Claims

### Claim 1

A method of diagnosing pulmonary fibrosis in a human subject comprising a) measuring a galectin-3 level (e.g. concentration) in a body sample from the human subject using a suitable test method, b) comparing the galectin-3 level to a predetermined reference level, and c) determining whether the galectin-3 level is indicative of diagnosing the subject with pulmonary fibrosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the indicative level of galectin-3 is at least 22 ng/ml.

### Claim 3

A method of predicting the prognosis of pulmonary fibrosis in a human subject comprising a) measuring a galectin-3 level (e.g. concentration) in a body sample from the human subject using a suitable test method, and b) determining whether the galectin-3 level is indicative of a poor prognosis or not for the human subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the indicative level of galectin-3 is at least 22 ng/ml.

### Claim 5

A method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis comprising a) measuring a galectin-3 level (e.g. concentration) in a body sample from the human subject using a suitable test method, b) comparing the galectin-3 level to a predetermined reference level, b) determine the presence or absence of a galectin-3 level indicative of the development or progression of exacerbation of symptoms, and c) repeating steps a) and b) to monitor or predict the development or progression of the exacerbation of symptoms in the human subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein when the indicative level of galectin-3 is below 22 ng/ml treatment of pulmonary fibrosis may be stopped, adjusted or put on hold.

### Claim 7 (depends on 5)

The method of claim 5, wherein when the indicative level of galectin-3 is at least 22 ng/ml.

### Claim 8 (depends on 5)

The method of claim 5, wherein when the indicative level of galectin-3 is at least 50 ng/ml prophylactic treatment of exacerbation of symptoms is initiated or increased.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is diagnosed with mild, moderate or aggressive forms of pulmonary fibrosis according to the level of galectin-3.

### Claim 10 (depends on 5)

The method of claim 5 wherein the predetermined reference level for galectin-3 is in the range from about 10.0 ng/mL to about 25.0 ng/mL, such as in the range from about 13.0 ng/mL to about 19.2 ng/mL.

### Claim 11 (depends on 1)

The method of claim 1 wherein the suitable test method is selected from an immunoassay, an immunohistochemical assay, a colorimetric assay, a turbidimetric assay, and flow cytometry.

### Claim 12

A method of detecting the presence and/or extent of pulmonary fibrosis to diagnose pulmonary fibrosis and/or predict the prognosis of pulmonary fibrosis in a human subject comprising a) measuring a galectin-3 level in a body sample from the human subject using a suitable test method, b) comparing the galectin-3 level to a predetermined reference level, and c) determining whether the galectin-3 level is indicative of diagnosing the subject with pulmonary fibrosis.

### Claim 13 (depends on 12)

The method of claim 12, wherein the indicative level of galectin-3 is at least about 22 ng/ml.

### Claim 14

A method of monitoring development or progression of or exacerbation of symptoms of pulmonary fibrosis in a human subject, comprising a) measuring a galectin-3 level in a body sample from the subject at least two times with sufficient interval(s) to measure a clinically relevant change, b) comparing the galectin-3 level to a predetermined reference level, and repeating steps a) and b) one or more times to monitor the development or progression of pulmonary fibrosis in the human subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the time period between two measurements is independently selected from about 2 weeks to about 2 years.

### Claim 16 (depends on 14)

The method of claim 14, wherein when the level of galectin-3 is below about 22 ng/ml treatment of pulmonary fibrosis is stopped, adjusted or put on hold.

### Claim 17 (depends on 14)

The method of claim 14, wherein in step a) further bio-markers are measured, where said markers are linked to Galectin-3 levels.

### Claim 18 (depends on 14)

The method of claim 14, wherein the predetermined reference level for galectin-3 is in the range from about 10.0 ng/mL to about 25.0 ng/mL.

### Claim 19 (depends on 14)

The method of claim 14, wherein the suitable test method is selected from an immunoassay, an immunohistochemical assay, a colorimetric assay, a turbidimetric assay, and flow cytometry.

### Claim 20 (depends on 14)

The method of claim 14, wherein the subject has a galectin-3 blood concentration determined to be within a target range from about 10 ng/ml to about 70 ng/ml.
